Fourth mRNA vaccination increases cross-neutralizing antibody titers against SARS-CoV-2 variants, including BQ.1.1 and XBB, in a very elderly population

被引:2
|
作者
Sutandhio, Silvia [1 ]
Furukawa, Koichi [1 ]
Kurahashi, Yukiya [1 ]
Marini, Maria Istiqomah [1 ]
Effendi, Gema Barlian [1 ]
Hasegawa, Natsumi [1 ]
Ishimaru, Hanako [1 ]
Nishimura, Mitsuhiro [1 ]
Arii, Jun [1 ]
Mori, Yasuko [1 ]
机构
[1] Kobe Univ, Ctr Infect Dis, Div Clin Virol, Grad Sch Med, 7-5-1 Kusunoki Cho,Chuo Ku, Kobe, Hyogo 6500017, Japan
关键词
COVID-19; Elderly; Omicron; Vaccination; Neutralizing antibody; EXPRESSION; FUSION;
D O I
10.1016/j.jiph.2023.05.004
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: Omicron variants with immune evasion have emerged, and they continue to mutate rapidly, raising concerns about the weakening of vaccine efficacy, and the very elderly populations are vulnerable to Coronavirus Disease 2019 (COVID-19). Therefore, to investigate the effect of multiple doses of mRNA vaccine for the newly emerged variants on these populations, cross-neutralizing antibody titers were examined against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) variants, including BQ.1.1 and XBB. Methods: Blood samples were taken from residents at four long-term care facilities in Hyogo prefecture, Japan (median age, 91 years), after 3rd (n = 67) and 4th (n = 48) mRNA vaccinations, from April to October 2022. A live virus microneutralization assay was performed to determine the neutralizing antibody titers in participants' sera.Results: After 3rd vaccination, cross-neutralizing antibody prevalence against conventional (D614G) virus, Delta, Omicron BA.2, BA.5, BA.2.75, BQ.1.1, and XBB were 100%, 97%, 81%, 51%, 67%, 4%, and 21%, respectively. After 4th vaccination, the antibody positivity rates increased to 100%, 100%, 98%, 79%, 92%, 31%, and 52%, respectively. The 4th vaccination significantly increased cross-neutralizing antibody titers against all tested variants. Conclusion: The positivity rates for BQ.1.1 and XBB increased after 4th vaccination, although the titer value was lower than those of BA.5 and BA.2.75.Considering the rapid mutation of viruses and the efficacy of vaccines, it may be necessary to create a system that can develop vaccines suitable for each epidemic in consideration of the epidemic of the virus.(c) 2023 The Authors. Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:1064 / 1072
页数:9
相关论文
共 50 条
  • [31] In Vitro Combinatorial Activity of Direct Acting Antivirals and Monoclonal Antibodies against the Ancestral B.1 and BQ.1.1 SARS-CoV-2 Viral Variants
    Fiaschi, Lia
    Biba, Camilla
    Varasi, Ilenia
    Bartolini, Niccolo
    Paletti, Chiara
    Giammarino, Federica
    Saladini, Francesco
    Zazzi, Maurizio
    Vicenti, Ilaria
    VIRUSES-BASEL, 2024, 16 (02):
  • [32] Broad-spectrum humanized monoclonal neutralizing antibody against SARS-CoV-2 variants, including the Omicron variant
    Wen, Kun
    Cai, Jian-Piao
    Fan, Xiaodi
    Zhang, Xiaojuan
    Luo, Cuiting
    Tang, Kai-Ming
    Shuai, Huiping
    Chen, Lin-Lei
    Zhang, Ricky Ruiqi
    Situ, Jianwen
    Tsoi, Hoi-Wah
    Wang, Kun
    Chan, Jasper Fuk-Woo
    Yuan, Shuofeng
    Yuen, Kwok-Yung
    Zhou, Hongwei
    To, Kelvin Kai-Wang
    FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2023, 13
  • [33] Cross-Neutralizing Activity Against SARS-CoV-2 Variants in COVID-19 Patients: Comparison of 4 Waves of the Pandemic in Japan
    Furukawa, Koichi
    Tjan, Lidya Handayani
    Sutandhio, Silvia
    Kurahashi, Yukiya
    Iwata, Sachiyo
    Tohma, Yoshiki
    Sano, Shigeru
    Nakamura, Sachiko
    Nishimura, Mitsuhiro
    Arii, Jun
    Kiriu, Tatsunori
    Yamamoto, Masatsugu
    Nagano, Tatsuya
    Nishimura, Yoshihiro
    Mori, Yasuko
    OPEN FORUM INFECTIOUS DISEASES, 2021, 8 (10):
  • [34] Neutralizing antibodies against SARS-CoV-2 variants following mRNA booster vaccination in adults older than 65 years
    Durier, Christine
    Ninove, Laetitia
    Lefebvre, Maeva
    Radenne, Anne
    Desaint, Corinne
    Ropers, Jacques
    Bauer, Rebecca
    Lebbah, Said
    Carette, Diane
    Lachatre, Marie
    Lecompte, Anne-Sophie
    Deplanque, Dominique
    Botelho-Nevers, Elisabeth
    Conrad, Anne
    Dussol, Bertrand
    Maakaroun-Vermesse, Zoha
    Melica, Giovanna
    Nicolas, Jean-Francois
    Verdon, Renaud
    Kiladjian, Jacques
    Loubet, Paul
    Schmidt-Mutter, Catherine
    Duale, Christian
    Ansart, Severine
    Priet, Stephane
    Levier, Axel
    Molino, Diana
    Vieillard, Louis-Victorien
    Parfait, Beatrice
    Lelievre, Jean-Daniel
    Tartour, Eric
    de Lamballerie, Xavier
    Launay, Odile
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [35] Neutralizing antibodies against SARS-CoV-2 variants following mRNA booster vaccination in adults older than 65 years
    Christine Durier
    Laetitia Ninove
    Maeva Lefebvre
    Anne Radenne
    Corinne Desaint
    Jacques Ropers
    Rebecca Bauer
    Said Lebbah
    Diane Carette
    Marie Lachatre
    Anne-Sophie Lecompte
    Dominique Deplanque
    Elisabeth Botelho-Nevers
    Anne Conrad
    Bertrand Dussol
    Zoha Maakaroun-Vermesse
    Giovanna Melica
    Jean-François Nicolas
    Renaud Verdon
    Jacques Kiladjian
    Paul Loubet
    Catherine Schmidt-Mutter
    Christian Dualé
    Séverine Ansart
    Stéphane Priet
    Axel Levier
    Diana Molino
    Louis-Victorien Vieillard
    Béatrice Parfait
    Jean-Daniel Lelièvre
    Eric Tartour
    Xavier de Lamballerie
    Odile Launay
    Scientific Reports, 12
  • [36] Retained avidity despite reduced cross-binding and cross-neutralizing antibody levels to Omicron after SARS-COV-2 wild-type infection or mRNA double vaccination
    Harthaller, Teresa
    Falkensammer, Barbara
    Bante, David
    Huber, Maria
    Schmitt, Melanie
    Benainouna, Habib
    Roessler, Annika
    Fleischer, Verena
    von Laer, Dorothee
    Kimpel, Janine
    Wuerzner, Reinhard
    Borena, Wegene
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [37] A Recombinant Protein XBB.1.5 RBD/Alum/CpG Vaccine Elicits High Neutralizing Antibody Titers against Omicron Subvariants of SARS-CoV-2
    Thimmiraju, Syamala Rani
    Adhikari, Rakesh
    Villar, Maria Jose
    Lee, Jungsoon
    Liu, Zhuyun
    Kundu, Rakhi
    Chen, Yi-Lin
    Sharma, Suman
    Ghei, Karm
    Keegan, Brian
    Versteeg, Leroy
    Gillespie, Portia M.
    Ciciriello, Allan
    Islam, Nelufa Y.
    Poveda, Cristina
    Uzcategui, Nestor
    Chen, Wen-Hsiang
    Kimata, Jason T.
    Zhan, Bin
    Strych, Ulrich
    Bottazzi, Maria Elena
    Hotez, Peter J.
    Pollet, Jeroen
    VACCINES, 2023, 11 (10)
  • [38] Vaccination of COVID-19 convalescent plasma donors increases binding and neutralizing antibodies against SARS-CoV-2 variants
    Di Germanio, Clara
    Simmons, Graham
    Thorbrogger, Chloe
    Martinelli, Rachel
    Stone, Mars
    Gniadek, Thomas
    Busch, Michael P.
    TRANSFUSION, 2022, 62 (03) : 563 - 569
  • [39] SARS-CoV-2 breakthrough infections following inactivated vaccine vaccination induce few neutralizing antibodies against the currently emerging Omicron XBB variants
    Shen, Fan
    Liang, Chun
    Yang, Cui-Xian
    Lu, Ying
    Li, An-Qi
    Duan, Ying
    Zhang, Mi
    Tian, Ren-Rong
    Dong, Xing-Qi
    Zheng, Yong-Tang
    Pang, Wei
    VIROLOGICA SINICA, 2024, 39 (01) : 173 - 176
  • [40] Post-vaccination SARS-CoV-2 antibody kinetics and protection duration against Omicron in elderly population
    Dimeglio, Chloe
    Tremeaux, Pauline
    Herin, Fabrice
    Da-Silva, Isabelle
    Porcheron, Marion
    Martin-Blondel, Guillaume
    Gernigon, Caroline
    Chapuy-Regaud, Sabine
    Villars, Helene
    Izopet, Jacques
    JOURNAL OF INFECTION, 2022, 85 (06) : 763 - 766